Anti-PCNA antibody GTX100539 from GeneTex

Published Figures
Supplier Images

Register or Sign In to View Figures.

Cancer management and research
January 01 2020

Fig 1: Cytotoxicity of combination GEM and Pita chemotherapy. (A) MIA PaCa-2 cells were cultured with increasing doses of GEM and Pita (0.1–0.5 µM) alone or in combination for 48 h. Then, the percentage of surviving cells in relation to the control was determined using CCK-8. Significant dose-dependent cell death was induced by GEM and Pita monotreatment. The combination of GEM + Pita showed enhanced additive cytotoxic effects for MIA PaCa-2 cells. (B) The CIs of GEM in combination with Pita were calculated using Chou–Talalay analyses; CI of < 1 indicates synergy, CI of >1 indicates antagonism, and an average CI of 1 is additive. Treatment with 0.25 µM GEM and 0.1 µM Pita resulted in antagonistic effects, whereas other combinations of varying drug concentrations had synergistic effects; 0.5 µM Pita combined with 0.25 µM or 0.5 µM GEM therapy had strong synergistic effects and at higher affected fractions of MIA PaCa-2 cells. (C) Cell migration analysis showing reduced MIA PaCa-2 cell migration capability treated with 0.25 µM or 0.5 µM GEM, 0.5 µM Pita, or their combination for 48 h compared with the untreated control group. Magnification 100×, bar = 100 µm. (D) Representative Western blot for hENT1, hCNT3, PCNA, dCK and RRM2 showing the expression of GEM uptake, cell proliferation and GEM resistance-related proteins in the MIA PaCa-2 cells treated with different doses of GEM and Pita for 48 h. GAPDH served as a loading control. (E) Significantly increased hENT1, hCNT3, dCK protein expressions and decreased PCNA, RRM2 protein expressions were detected in the GEM–Pita combination treatment compared with other groups. The density for the control group was set at 1; Values are means ± SD from three replicates. §, *, † and d represent significant difference p-values, P ? 0.05, compared to the only CON, G0.25- or G0.5- or P0.5-treated group.Abbreviations: GEM, gemcitabine; Pita, pitavastatin; CCK-8, cell counting kit-8; CIs, combination indices; hENT1, human equilibrative nucleoside transporter 1; hCNT3, human concentrative nucleoside transporter 3; PCNA, proliferating cell nuclear antigen; dCK, deoxycytidine kinase; RRM2, ribonucleotide reductase subunit M2.
Register or Sign In to View Figures.

Molecular medicine reports
March 01 2016

Fig 2: Effect of ADSC transplantation on the PCNA-labeling index at 24, 72, and 168 h postoperatively. Data are expressed as the mean ± standard deviation of the results from five animals. *P<0.01, vs. PH group; **P<0.01, vs. R-PH group. ADSC, adipose tissue-derived mesenchymal stem cell; PCNA, proliferating cell nuclear antigen; PH, partial hepatectomy; R-PH, repeat PH.
Register or Sign In to View Figures.

Frontiers in pharmacology
January 01 2021

Fig 3: Upregulation of IRF9 accelerate and downregulation attenuate the proliferation of HPASMCs. (A,B,I and J) The protein level of IRF9 in HPASMCs with IRF9 overexpression (A) or knockdown (I) were detected by using western blot (n = 3 independent experiments); the IRF9 protein level was quantified (B,J). (C,K) The counts of cell number after HPAMSCs treated with Lenti-IRF9-Flag (C) or Lenti-shIRF9 (K) for indicated time under normoxia condition; Lenti-Flag and Lenti-PLKO.1 serve as control group (n = 3 independent experiments). (D,L) CCK-8 assay shows the absorbances at 450 nm of Lenti-Flag/Lenti-PLKO.1 and Lenti-IRF9-Flag/Lenti-shIRF9 HPASMCs under normoxia condition (n = 3 independent experiments). (E,M) EdU incorporation assay of HPASMCs infected with Lenti-Flag/Lenti-IRF9-Flag (E) or Lenti-PLKO.1/Lenti-shIRF9 (M) under normoxia condition, in which nuclei were stained with DAPI (blue) and EdU merged with DAPI appears pink. Scale bar, 20 µm. (F,N) The positive EdU staining rate was measured in HPASMCs after IRF9 overexpression (F) or knockdown (N) (n = 3 independent experiments). (G,O) Protein levels of PCNA and p-Histone H3 were determined by western blot after overexpressing (G) or knockdown (O) of IRF9 in HPASMCs under normoxia condition. (H,P) The expression levels were normalized to ß-Actin and quantified (n = 3 independent experiments). ß-Actin serves as loading control. Values are means ± SD; ***p < 0.001, **p < 0.01, *p < 0.05.
Register or Sign In to View Figures.

Frontiers in oncology
January 01 2022

Fig 4: Additional inhibitory effect of the combination treatment of Cisplatin (CDDP) and 5-methoxytryptophan (5-MTP) in 4NQO-induced tongue oral squamous cell carcinoma (OSCC) mouse model. (A) Morphological observation of the DMSO- or drug-treated group in 4NQO-induced cancer mouse model. (B) Digital outlines of representative tongues of DMSO- or drug-treated mice. Asterisks indicate significant difference in drug-treated group singly in comparison with 4NQO-treated group. *P < 0.05 (C) hematoxylin–eosin or immunohistochemical staining with PCNA and p-STAT3 antibodies of tongue cancer with DMSO or drug treatment.
Register or Sign In to View Figures.

Frontiers in pharmacology
January 01 2021

Fig 5: IRF9 overexpression increased the proliferation of RPASMCs. (A) After overexpressing IRF9 (Lenti-IRF9-Flag) or not (Lenti-Flag) in RPASMCs, the expression level of IRF9 and the exogenous label protein Flag was determined using western blot (n = 3 independent experiments). (B) The expression levels of IRF9 were normalized to ß-Actin and quantified (n = 3 independent experiments). (C) Cell numbers were counted at indicated time point after IRF9-overexpressing or not in RPASMCs under normoxia condition (n = 3 independent experiments). (D) CCK-8 assay was performed and the absorbance (OD value) at 450 nm was measured to shows the proliferation activity of Lenti-Flag and Lenti-IRF9-Flag RPASMCs under normoxia condition (n = 3 independent experiments). (E) EdU incorporation assay shows the ratio of cells incorporated EdU in Lenti-Flag and Lenti-IRF9-Flag RPASMCs under normoxia condition, in which nuclei were stained with DAPI (blue) and EdU merged with DAPI appears pink. Scale bar = 20 µm. (F) The positive EdU staining rates were quantified (n = 3 independent experiments). (G) The protein levels of proliferation biomarkers PCNA and p-Histone H3 were determined using western blot after overexpressing IRF9 or not in RPASMCs under normoxia condition. (H) The expression levels of PCNA and p-Histone H3 were quantified and normalized to ß-Actin (n = 3 independent experiments). Values are means ± SD; ***p < 0.001, **p < 0.01, *p < 0.05.

Be the first to write a review!

Citations:

(73)

Figures:

Supplier Page

Supplier Page from
GeneTex for
Anti-PCNA antibody

Description

GeneTex's Anti-PCNA antibody is a Rabbit Polyclonal antibody. The Anti-PCNA antibody was generated using proliferating cell nuclear antigen, ATLD2 as the antigen. The Anti-PCNA antibody from GeneTex is a Rabbit Polyclonal antibody to PCNA. The Anti-PCNA antibody Recognizes Human, Mouse, Rat, Drosophila, Golden Syrian Hamster. The Anti-PCNA antibody has been validated for the following Applications: WB, ICC/IF, IHC-P, IHC-Fr, IP, FISH, IHC

Product Specs
ItemAnti-PCNA antibody
CompanyGeneTex
Price Pricing Info Supplier Page
Catalog NumberGTX100539
Quantity100 µl
ApplicationsWB, ICC/IF, IHC-P, IHC-Fr, IP, FISH, IHC
Concentration0.11mg/ml
Conjugate/TagUnconjugated
PurityPurified by antigen-affinity chromatography
ReactivityHuman, Mouse, Rat, Drosophila, Golden Syrian Hamster
TargetPCNA
IsotypeIgG
HostRabbit
Antibody TypePrimary Antibodies
ImmunogenRecombinant protein encompassing a sequence within the center region of human PCNA. The exact sequence is proprietary
NCBI Full Gene Nameproliferating cell nuclear antigen
NCBI Gene Aliasesproliferating cell nuclear antigen, ATLD2, ATLD2
ClonalityPolyclonal
Research AreaCell Biology, Loading Control Antibodies, Organelle Markers
FormatPBS, 1% BSA, 20% Glycerol, 0.025% ProClin 300
Gene NamePCNA
Molecular Weight29

Add to Compare List

GeneTex

GeneTex, Inc. 2456 Alton Parkway

Irvine, California 92606

United States

Phone: 1-877-GeneTex (436-3839) or 949-553-1900
Fax: 949-309-2888

Company Profile

Website: http://www.genetex.com

(1) Antioxidant and anti-inflammatory effects of allicin in the kidney of an experimental model of metabolic syndromePeerJSeptember 27, 2023Abraham Said Arellano Buendia, Juan Gabriel Juárez Rojas, Fernando García-Arroyo, Omar Emiliano Aparicio Trejo, Fausto Sánchez-Muñoz, Raúl Argüello-García, Laura Gabriela Sánchez-Lozada, Rafael Bojalil, Horacio Osorio-AlonsoKIM-1 (GTX85067), Nrf2 (GTX103322), Keap1 (GTX60660), NFκB p65 (GTX102090), IκB (GTX82797), and PCNA (GTX100539) were from GeneTex (Irvine, CA, USA). Goat anti-rabbit and goat anti-mouse IgG-HRP were purchased from

(2) Immunohistochemical Expression of Glutathione Peroxidase-2 (Gpx-2) and Its Clinical Relevance in Colon Adenocarcinoma PatientsInternational Journal of Molecular SciencesSeptember 27, 2023Marlena Brzozowa-Zasada, Angela Ianaro, Adam Piecuch, Marek Michalski, Natalia Matysiak, Katarzyna StęplewskaGTX100292, final dilution—1:800, Irvine, CA, USA) and PCNA (GeneTex, polyclonal antibody, Cat. No. GTX100539, final dilution—1:600, Irvine, CA, USA). For visualisation of protein expression, the sections were

(3) Immunohistochemical Expression of Upregulated Gene 4 Protein Expression (URG4/URGCP) and Its Association with 5-Year Survival in Patients with Colon AdenocarcinomaJournal of Clinical MedicineAugust 23, 2023Marlena Brzozowa-Zasada, Adam Piecuch, Marek Michalski, Katarzyna Stęplewska, Natalia Matysiak, Marek KucharzewskiLane Suite 200; Peachtree Corners, GA 30092, USA) and PCNA (polyclonal antibody from GeneTex. Cat. No. GTX100539, final dilution 1:600, Irvine, CA, USA). To visualise protein expression, sections were developed using

(4) Immunolocalization of Some Epidermal Proteins and Glycoproteins in the Growing Skin of the Australian Lungfish (Neoceratodus forsteri)J Dev BiolAugust 14, 2023Lorenzo Alibardiantibody against rat nestin (rat-401, DSHB, USA) was also utilized. Finally, a rabbit PCNA antibody (GTX100539, GeneTex, Irvine, CA, USA) was employed to detect sites of cell proliferation within the skin. Tissue

(5) Immunohistochemical Expression of Glutathione Peroxidase 1 (Gpx-1) as an Independent Prognostic Factor in Colon Adenocarcinoma PatientsPharmaceuticals (Basel)May 12, 2023Marlena Brzozowa-Zasada, Adam Piecuch, Karolina Bajdak-Rusinek, Kamil Janelt, Marek Michalski, Olesya Klymenko, Natalia MatysiakNo. GTX03346, final dilution 1:600, Irvine, CA, USA) and PCNA (GeneTex. polyclonal antibody. Cat. No. GTX100539, final dilution 1:600, Irvine, CA, USA). For visualisation of protein expression, the sections were

(6) The Clinical Application of Immunohistochemical Expression of Notch4 Protein in Patients with Colon AdenocarcinomaInternational Journal of Molecular SciencesApril 19, 2023Marlena Brzozowa-Zasada, Adam Piecuch, Marek Michalski, Natalia Matysiak, Marek Kucharzewski, Marek J. ŁosUSA), which targeted cleaved N-terminous epitope, and PCNA (GeneTex. polyclonal antibody. Cat. No. GTX100539, final dilution 1:600, Irvine, CA, USA). For visualisation of protein expression, the sections were

(7) Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesisNature geneticsApril 1, 2023Nee K, Ma D, Nguyen QH, Pein M, Pervolarakis N, Insua-Rodríguez J, Gong Y, Hernandez G, Alshetaiwi H, Williams J, et al.

(8) Methyltransferase-like 3 suppresses phenotypic switching of vascular smooth muscle cells by activating autophagosome formationCell proliferationApril 1, 2023Fang ZM, Zhang SM, Luo H, Jiang DS, Huo B, Zhong X, Feng X, Cheng W, Chen Y, Feng G, et al.(Bio‐Rad). The antibodies used in this study including anti‐proliferating cell nuclear antigen (PCNA; GTX100539; 1:1000), anti‐MMP9 (GTX100458; 1:1000), anti‐MMP2 (GTX634832; 1:1000) and anti‐MYH10 (GTX634160; 1:1000)

(9) Tubeimoside I Ameliorates Doxorubicin-Induced Cardiotoxicity by Upregulating SIRT3Oxidative medicine and cellular longevityJanuary 1, 2023Zhang W, Fan Z, Wang F, Yin L, Wu J, Li D, Song S, Wang X, Tang Y, Huang C.#GTX101147), anti-total-NF-κB P65 (T-P65, #GTX102090), antiproliferating cell nuclear antigen (PCNA, #GTX100539), and anti-phospho-NF-κB P65 (P-P65, #GTX133899) were purchased from GeneTex (California, USA); anti-B

(10) Cullin 4b-RING ubiquitin ligase targets IRGM1 to regulate Wnt signaling and intestinal homeostasisCell death and differentiationSeptember 1, 2022Fan Y, Huo X, Guo B, Zhang X, Yang Y, Lian J, Meng X, Shao Y, Zou Y, Guo H, et al.

(11) JIB-04, a histone demethylase Jumonji C domain inhibitor, regulates phenotypic switching of vascular smooth muscle cellsClinical epigeneticsAugust 13, 2022He Y, Yi X, Zhang Z, Luo H, Li R, Feng X, Fang ZM, Zhu XH, Cheng W, Jiang DS, et al.got from ABclonal. H3K9me3 (GTX121677), MMP2 (GTX634832), MYH10 (GTX634160), MMP9 (GTX100458), PCNA (GTX100539) were purchased from GeneTex. P-H3 (sc-8656-R) was obtained from Santa Cruz. LAMP3 (AP1827A) was bought

(12) Modulation of POPDC1 Expression by Phenothiazine and Trifluoperazine Suppress Colon Cancer Growth and MigrationAsian Pacific journal of cancer prevention : APJCPAugust 1, 2022Thomas FM, Sudi S, Muhamad Salih FA, Palasuberniam P, Suali L, Mohd Sani MH, Sunggip C.4°C with primary antibodies of β-actin diluted (1:5000; #E-AB-20058) from Elabscience, PCNA (1:5000; #GTX100539), CD1 (1:5000; #GTX108624), from GeneTex, and POPDC1 (1:1000; #PA5-80386) from Thermo Fisher Scientific.

(13) Carpaine Promotes Proliferation and Repair of H9c2 Cardiomyocytes after Oxidative InsultsPharmaceuticals (Basel, Switzerland)February 15, 2022Sudi S, Chin YZ, Wasli NS, Fong SY, Shimmi SC, How SE, Sunggip C.from Cell Signalling, polyclonal antibodies against cyclin D1 (1:1000; GTX108624) and PCNA (1:1000; GTX100539) from GeneTex and beta-actin (Elabscience, 20058, Texas, USA) as a loading control overnight at 4 °C.

(14) 5-Methoxytryptophan Sensitizing Head and Neck Squamous Carcinoma Cell to Cisplatitn Through Inhibiting Signal Transducer and Activator of Transcription 3 (STAT3)Frontiers in oncologyJanuary 1, 2022Su YC, Wang CC, Weng JH, Yeh SA, Chen PJ, Hwang TZ, Chen HC.AP0637), p-p65 (Cell Signaling; 1:1000, 3033T), p-p38 (ABclonal; 1:1000, AP0526), PCNA (GeneTex; 1:3000, GTX100539), GAPDH (GeneTex; 1:10000, GTX100118). Enhanced chemiluminescence was used to detect the signals. The

(15) Protective effect of sargahydroquinoic acid against Aβ_25-35-evoked damage via PI3K/Akt mediated Nrf2 antioxidant defense systemBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapieDecember 1, 2021Yoon JH, Youn K, Jun M.

(16) Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistanceCancer lettersNovember 1, 2021Wang LT, Liu KY, Chiou SS, Huang SK, Hsu SH, Wang SN.

(17) Upregulation of SNTB1 correlates with poor prognosis and promotes cell growth by negative regulating PKN2 in colorectal cancerCancer cell internationalOctober 18, 2021Liu L, Chen Y, Lin X, Wu M, Li J, Xie Q, Sferra TJ, Han Y, Liu H, Cao L, et al.regulatory effects. Methods Materials and reagents The antibodies against SNTB1 (GTX46866) and PCNA (GTX100539) were purchased from GeneTex (San Antonio, TX, USA). The antibodies against Caspase-3 (9662), Caspase-9

(18) Metformin Potentiates the Anticancer Effect of Everolimus on Cervical Cancer In Vitro and In VivoCancersSeptember 14, 2021Chen YH, Wu JX, Yang SF, Chen ML, Chen TH, Hsiao YH.(#4695), phospho-JNK (#4668), JNK (#9258; Cell Signaling, Danvers, MA, USA); P21Cip1 (GTX629543), PCNA (GTX100539; GeneTex, Inc., Irvine, CA, USA); PIK3CA (NBP2-19804; Novus, CO, USA); MitoProfile® Total OXPHOS rodent

(19) Qingda granule attenuates cardiac fibrosis via suppression of the TGF-β1/Smad2/3 signaling pathway in vitro and in vivoBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapieMay 1, 2021Chen X, Long L, Cheng Y, Chu J, Shen Z, Liu L, Li J, Xie Q, Liu H, Wu M, et al.

(20) Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progressionScientific reportsMarch 15, 2021Kase Y, Uzawa K, Wagai S, Yoshimura S, Yamamoto JI, Toeda Y, Okubo M, Eizuka K, Ando T, Nobuchi T, et al.

Be the First to Write a Review!

Cancer management and research

Molecular medicine reports

Frontiers in pharmacology

Frontiers in oncology

Frontiers in pharmacology

Anti-PCNA antibody from GeneTex

Description

GeneTex

Citations (73)

Reviews

Anti-PCNA antibody from GeneTex

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map